Clinical Laboratory Improvement Amendments (CLIA) has not impeded patient access to tests says Office of Inspector General (OIG)
This article was originally published in Clinica
Within the next few months, the US Department of Health & Human Services (HHS) Office of Inspector General (OIG) will announce that strict new rules and federal regulation of clinical laboratories have apparently not limited patient access to certain tests, reports Clinica's Washington correspondent, Duffy Miller.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.